4 - Zivo Bioscience, Inc. (0001101026) (Issuer)

4 - Zivo Bioscience, Inc. (0001101026) (Issuer)

4 - Zivo Bioscience, Inc. (0001101026) (Issuer)

4 - Zivo Bioscience, Inc. (0001101026) (Issuer)

4 - Zivo Bioscience, Inc. (0001101026) (Issuer)

4 - Zivo Bioscience, Inc. (0001101026) (Issuer)

4 - Zivo Bioscience, Inc. (0001101026) (Issuer)

4 - Zivo Bioscience, Inc. (0001101026) (Issuer)

4 - Zivo Bioscience, Inc. (0001101026) (Issuer)

4 - Zivo Bioscience, Inc. (0001101026) (Issuer)

DEF 14A - Zivo Bioscience, Inc. (0001101026) (Filer)

DEFA14A - Zivo Bioscience, Inc. (0001101026) (Filer)

10-K - Zivo Bioscience, Inc. (0001101026) (Filer)

8-K - Zivo Bioscience, Inc. (0001101026) (Filer)

8-K - Zivo Bioscience, Inc. (0001101026) (Filer)

SCHEDULE 13D/A - Zivo Bioscience, Inc. (0001101026) (Subject)

8-K - Zivo Bioscience, Inc. (0001101026) (Filer)

8-K - Zivo Bioscience, Inc. (0001101026) (Filer)

10-Q - Zivo Bioscience, Inc. (0001101026) (Filer)

8-K - Zivo Bioscience, Inc. (0001101026) (Filer)

Maxim Group initiated coverage of Zivo Bioscience with a rating of Buy and set a new price target of $9.00

4 - Zivo Bioscience, Inc. (0001101026) (Issuer)

4 - Zivo Bioscience, Inc. (0001101026) (Issuer)

5 - Zivo Bioscience, Inc. (0001101026) (Issuer)

4 - Zivo Bioscience, Inc. (0001101026) (Issuer)

4 - Zivo Bioscience, Inc. (0001101026) (Issuer)

4 - Zivo Bioscience, Inc. (0001101026) (Issuer)

4 - Zivo Bioscience, Inc. (0001101026) (Issuer)

4 - Zivo Bioscience, Inc. (0001101026) (Issuer)

4 - Zivo Bioscience, Inc. (0001101026) (Issuer)

4 - Zivo Bioscience, Inc. (0001101026) (Issuer)

ZIVO Bioscience, Inc. (OTCQB:ZIVO), a pioneering biotech/agtech R&D company dedicated to developing therapeutic, medicinal and nutritional product candidates derived from proprietary algal cultures, today announced positive results from its second collaborative study with the University of Delaware evaluating the efficacy of several formulations of ZIVO's proprietary active ingredients in mitigating the spread of Low Pathogenicity Avian Influenza (LPAI) virus among poultry. Building upon the outcomes of the initial study, this second study aimed to assess and compare the performance of three different ZIVO formulations in both directly challenged and contact-exposed birds. The study affirm

ZIVO Bioscience, Inc. (OTCQB:ZIVO), a pioneering biotech/agtech R&D company dedicated to developing therapeutic, medicinal and nutritional product candidates derived from proprietary algal cultures, announces plans for a second collaborative study with the University of Delaware. This new study aims to further explore the potential applications of ZIVO's proprietary active ingredients in mitigating the spread of Low Pathogenicity Avian Influenza (LPAI) virus among poultry. ZIVO's previous study with the University of Delaware demonstrated a significant reduction in viral shedding and a delay in disease transmission among treated birds. This new study is designed to further optimize formul

Zivo Bioscience, Inc. (OTCQB:ZIVO), a pioneering biotech/agtech R&D company dedicated to developing therapeutic, medicinal and nutritional product candidates derived from proprietary algal cultures, today announced its participation in The Microcap Conference 2025 being held January 28-30, 2025, in Atlantic City, N.J. Management will deliver a corporate presentation and engage in one-on-one meetings with institutional and individual investors to discuss the company's recent developments, growth strategy, and investment opportunities. Event: The Microcap Conference 2025 Location: Studio 1, Borgata Hotel Casino & Spa Date: Thursday January 30, 2025 Time: 2:30 PM Eastern Time Investors i

Expects to enter into formal negotiations with a global animal health company in January 2025 and to finalize an agreement in the first quarter of 2025 Zivo Bioscience, Inc. (OTCQB:ZIVO), a pioneering biotech/agtech R&D company dedicated to developing therapeutic, medicinal and nutritional product candidates derived from proprietary algal cultures, today provided an update on activities related to licensing its product targeting coccidiosis in broiler chickens. Following the announcement in August 2024 of positive results from a 42-day coccidiosis study, the Company has been engaged in discussions with a number of major global animal health companies regarding a potential exclusive lice

Zivo Bioscience, Inc. (OTCQB: ZIVO), a pioneering biotech/agtech R&D company dedicated to developing therapeutic, medicinal and nutritional product candidates derived from proprietary algal cultures, reports favorable results from a study conducted in collaboration with the University of Delaware that evaluated the potential of ZIVO's proprietary active ingredients to reduce the transmission of Low Pathogenicity Avian Influenza (LPAI) virus among poultry. Key findings of statistical significance from the study include: A reduction in viral titers (viral shedding) in infected birds receiving ZIVO's products compared with untreated infected controls. A delay in transmission of LPAI wh

ZIVO Bioscience, Inc. (OTCQB:ZIVO), a pioneering biotech/agtech R&D company dedicated to developing therapeutic, medicinal and nutritional product candidates derived from proprietary algal cultures, reports favorable results from its latest 42-day study with its product targeting coccidiosis in broiler chickens. The study, which was conducted in collaboration with a major global animal health company and replicated real-world poultry production environments, further validates the efficacy of ZIVO's non-antibiotic, immune-modulating product designed for the treatment of coccidiosis. Funded by the major animal health company, the study focused on the overall health and productivity of birds

ZIVO Bioscience, Inc. (NASDAQ:ZIVO), a pioneering biotech/agtech R&D company dedicated to developing therapeutic, medicinal and nutritional product candidates derived from proprietary algal cultures, announces the initiation of a 42-day confirmatory study targeting coccidiosis in collaboration with a major global animal health company. This new study aims to further validate the efficacy of ZIVO's non-antibiotic, immune-modulating product designed for the prevention and treatment of coccidiosis in broiler chickens. Building upon the positive outcomes of previous trials, this study replicates real-world conditions to ensure the product's effectiveness in commercial poultry production envir

Reduction in intestinal damage enables poultry farms to optimize feed utilization Zivo Bioscience, Inc. (OTCQB:ZIVO) (the "Company"), a biotech/agtech R&D company engaged in the development of therapeutic, medicinal and nutritional product candidates derived from proprietary algal cultures, announces additional findings from its 42-day coccidiosis challenge study that demonstrate the product's positive impact on the cost of broiler production as an alternative to commonly-used antibiotics. ZIVO's product candidate for use in poultry feed is designed to boost immune response, allowing birds to effectively combat coccidiosis and reduce the negative effects of the disease without the use o

Zivo Bioscience, Inc. (OTCQB:ZIVO) (the "Company"), a biotech/agtech R&D company engaged in the development of therapeutic, medicinal and nutritional product candidates derived from proprietary algal cultures, announces it has uplisted the trading of shares of its common stock from the OTC® Pink Market to the OTCQB® Venture Market (OTCQB), effective as of the opening of trading on Friday, January 26, 2024. Following this uplisting, ZIVO Bioscience continues to trade under the ticker symbol "ZIVO" and warrants continue to trade under the ticker symbol "ZIVOW". "In line with our strategic objectives, we have successfully completed the transition of our shares to the OTCQB market. This move

Zivo Bioscience, Inc. (OTC:ZIVO) (the "Company"), a biotech/agtech R&D company engaged in the development of therapeutic, medicinal and nutritional product candidates derived from proprietary algal cultures, announces positive efficacy results following its recent 42-day coccidiosis challenge study further demonstrating the effectiveness of its novel immune-modulating treatment for coccidiosis in broiler chickens. ZIVO's product candidate for use in poultry feed is designed to boost immune response, allowing birds to effectively combat coccidiosis and reduce the negative effects of the disease without the use of antibiotics. With these and earlier test results, ZIVO will pursue a partnershi

SC 13D/A - Zivo Bioscience, Inc. (0001101026) (Subject)

SC 13D - Zivo Bioscience, Inc. (0001101026) (Subject)

SC 13D - Zivo Bioscience, Inc. (0001101026) (Subject)

SC 13D - Zivo Bioscience, Inc. (0001101026) (Subject)

SC 13D/A - Zivo Bioscience, Inc. (0001101026) (Subject)

SC 13D/A - Zivo Bioscience, Inc. (0001101026) (Subject)

SC 13D - Zivo Bioscience, Inc. (0001101026) (Subject)

SC 13D/A - Zivo Bioscience, Inc. (0001101026) (Subject)

SC 13D/A - Zivo Bioscience, Inc. (0001101026) (Subject)